Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Epilepsy (Jan 2021)

Trends That Matter for MCO's Role in COVID Vaccine Rollout

Radar On Market Access: Centene, UnitedHealth Ring in New Year With M&A

Radar On Market Access: FDA Approves First Oral Treatment for HAE Attack Prevention

MMIT Reality Check on Non-Small Cell Lung Cancer ALK+ or ROS1+ (Jan 2021)

Perspectives on New-to-Market Oral Drugs

Radar On Market Access: Supreme Court's ACA Ruling May Upend Biosimilars Market

Radar On Market Access: Despite New Approvals, Plans Still Favor Generics for Epilepsy

MMIT Reality Check on Metastatic Prostate Cancer (Dec 2020)

Trends That Matter for COVID Vaccine Distribution

Radar On Market Access: Surprise Medical Billing Comes to An End, Insurers Oppose Arbitration Mechanism

Radar On Market Access: PBMs Continue Integration, Face More Regulatory Challenges in 2020

MMIT Reality Check on Migraine Prevention (Dec 2020)

Perspectives on Amazon Pharmacy

Radar On Market Access: MCO Messaging Plays Key Role in COVID Vaccine Rollout

Radar On Market Access: Biden Probably Won't Roll Back New Prior Authorization Proposal

MMIT Reality Check on Breast Cancer HR+/HER2+ (Dec 2020)

Trends That Matter: Centene's ACA Expansion

Radar On Market Access: New-to-Market Oral Drugs May Not Always Have a Leg Up on Injectables

Radar On Market Access: First Round of Vaccines Are Expected to Be Free to the Public

MMIT Reality Check on Nonmetastatic Prostate Cancer (Dec 2020)

Perspectives on Biden Administration's Drug-Pricing Moves

Radar On Market Access: Employers Show Interest in Moving to ICHRAs

Radar On Market Access: Insurers Will Play Key Role in COVID Vaccine Distribution, Reimbursement

MMIT Reality Check on Ovarian Cancer (Dec 2020)

Trends That Matter for Growth Hormone Deficiency Treatments

Radar On Market Access: For PBMs, Amazon Pharmacy May Pose Only Indirect Threat

Radar On Market Access: MA Insurers Report Strong Performance, Predict Enrollment Growth

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

Perspectives on CMS Insulin Demo

Radar On Market Access: Teledermatology Program Reduces Patient Wait Time But Doesn't Increase Utilization

Radar On Market Access: Centene Expands ACA Footprint But Faces More Competition

MMIT Reality Check on Multiple Myeloma (Nov 2020)

Trends That Matter for Employer Health Benefits

Radar On Market Access: Insurer-Affiliated PBMs Propel Parent Firms' Revenues in Third Quarter

Radar On Market Access: Biden Administration's Drug-Pricing Moves May Be Limited

MMIT Reality Check on Cystic Fibrosis (Nov 2020)

Perspectives on MA Star Ratings

Radar On Market Access: What's Next for Health Insurers in a Likely Split Congress?

Radar On Market Access: Humana Reports Strong Earnings, But Expects Fourth-Quarter Loss

MMIT Reality Check on Chronic Lymphocytic Leukemia (Nov 2020)

Trends That Matter for Major PBMs' 2021 Formulary

Radar On Market Access: FDA's Approval of Sogroya May Change GH Class Management

Radar On Market Access: Centene Talks ACA's Future, Medicaid Rates in 3Q Earnings Call

MMIT Reality Check on Hepatocellular Carcinoma (Oct 2020)

Perspectives on the Future of ACA

Radar On Market Access: Employers Aim to Narrow Networks, Emphasize COEs, Expand Virtual Care Benefits

Radar On Market Access: Costlier PDPs, Cheaper MA-PDs Participate in CMS Insulin Demo

MMIT Reality Check on Psoriasis (Oct 2020)

Trends That Matter for CAR-T Therapies

Radar On Market Access: Racial Disparities Are Highlighted by Pandemic

Radar On Market Access: Average MA Star Ratings Fall Due to Increased Weights, Cut Points

MMIT Reality Check on Hemophilia A (Factor VIII) (Oct 2020)

Perspectives on Provider Consolidation

Radar On Market Access: Trump's $200 Medicare Drug Card Proposal Prompts Criticism

Radar On Market Access: CVS, OptumRx Exclude Brand-Name Inhalers From 2021 Formularies, Switch Up Diabetes Supplies

MMIT Reality Check on IBS-C (Oct 2020)

Trends That Matter on Trump Administration's Rebate Order

Radar On Market Access: COVID-19 Pandemic May Lower Health Care Costs, But Deferral Impact Exists

Radar On Market Access: If Preexisting Condition Protections Vanish, Health Insurers Probably Won't Cheer

MMIT Reality Check on Merkel Cell Carcinoma (Oct 2020)

Perspectives on Amazon-Sharp HealthCare Deal

Radar On Market Access: New Manufacturing Approach May Drive Down CAR-T Therapies' Prices

Radar On Market Access: Experts Remain Skeptical That SCOTUS Will Scuttle Entire ACA

MMIT Reality Check on Sickle Cell Disease (Sep 2020)

Trends That Matter for COVID Cost-Sharing Waivers

Radar On Market Access: Pandemic, Market Stability Encourage Major Insurers to Expand ACA Footprints

Radar On Market Access: As Payer M&A Slows Down, What's Next?

MMIT Reality Check on Schizophrenia (Sep 2020)

Perspectives on PBM Performance Amid COVID-19

Radar On Market Access: Prime Therapeutics Introduces Real Time Benefit Tool

Radar On Market Access: Trump's International Drug Pricing Order Is Still Missing; Rebate Order Draws Fire

MMIT Reality Check on Acute Migraine (Sep 2020)

Trends That Matter for Large Employers in 2021

Radar On Market Access: Amazon Moves Further Into Health Care Data, Sharp Deal Shows

Radar On Market Access: Some COVID Cost-Sharing Waivers Would Expire Soon

MMIT Reality Check on Breast Cancer HR+/HER2- (Sep 2020)

Perspectives on Telehealth Executive Order

Radar On Market Access: Insurers Expand Flu Vaccination Outreach to Blunt COVID-19 Effects

Radar On Market Access: USPS Delivery Slowdown Is Unlikely to Cause Major Rx Fill Disruption

MMIT Reality Check on Non-Small Cell Lung Cancer Systemic Therapy (Aug 2020)

Trends That Matter for Prostate Cancer Treatments

Radar On Market Access: Payers Face Challenges to Enroll Newly Uninsured

Radar On Market Access: Large Employers Expect Cost Uncertainty, More Virtual Care in 2021

MMIT Reality Check on Ulcerative Colitis (Aug 2020)

Perspectives on UnitedHealth, Humana's Chronic Conditions Programs

Radar On Market Access: COVID-19 Pandemic Amps Up Interest in Home Care

Radar On Market Access: Anthem, Cigna, CVS Report Strong PBM Performance Amid COVID-19

MMIT Reality Check on Duchenne Muscular Dystrophy (Aug 2020)

Trends That Matter for Major Insurers' Performance Amid COVID-19

Radar On Market Access: Trump Administration Issues Telehealth Executive Order, More Acts Are Needed

Radar On Market Access: FDA Approved Two PARP Inhibitors for Prostate Cancer

MMIT Reality Check on Parkinson's Disease (Aug 2020)

Perspectives on Remdesivir's $3,120 Price Tag

Radar On Market Access: Anthem Warns of Greater Commercial Enrollment Drop in Second Half

Radar On Market Access: Experts Are Skeptical of Trump Administration's Drug Pricing Executive Orders

MMIT Reality Check on Kidney Cancer (July 2020)

Trends That Matter for Medicaid MCOs

Radar On Market Access: UnitedHealth, Humana Launch Programs for Chronic Conditions

Radar On Market Access: Manufacturers, Payers Wait on Federal COVID-19 Vaccine Distribution Plan

MMIT Reality Check on Bipolar Disorder (July 2020)

Perspectives on Trump Admin's COVID-19 Testing Payment Guidance

Radar On Market Access: Despite Coronavirus Surge, UnitedHealth Expects Care Utilization to Rebound This Year

Radar On Market Access: Trump Admin's COVID-19 Testing Payment Guidance Stirs Debate

MMIT Reality Check on Psoriatic Arthritis (July 2020)

Trends That Matter for Racial Disparities in MA Plans

Radar On Market Access: IngenioRx Acquires ZipDrug to Improve Medication Adherence, Affordability

Radar On Market Access: Remdesivir's $3,120 Price Tag Stirs Debate

MMIT Reality Check on Acute Lymphoblastic Leukemia (July 2020)

Perspectives on MedImpact’s New Program to Accelerate Pharmacogenomics

Radar On Market Access: Upheld Transparency Rule Is Slated to Reshape Payer-Provider Negotiations

Radar On Market Access: Reports Show Medicaid MCOs Are 'Dominant,' Increase Affordability

MMIT Reality Check on Hemophilia A or B With Inhibitors (July 2020)

Trends That Matter for DMD Therapies

Radar On Market Access: Insurers Are Required to Cover Only 'Medically Necessary' COVID-19 Tests

Radar On Market Access: CMS Proposes New Medicaid Best Price Rules for Pricey Therapies

MMIT Reality Check on Ankylosing Spondylitis (June 2020)

Perspectives on COVID-19 Vaccine Rollout

Radar On Market Access: Telehealth Regulation and Reimbursement Issue Sparks Debates

Radar On Market Access: CMS Report Shows Increasing Racial Disparities in MA Plans

MMIT Reality Check on Urothelial/Bladder Cancer (June 2020)

Trends That Matter: Enrollment Shift Into ACA Exchanges

Radar On Market Access: Pricey Treatments Face Challenges on Cost Sharing and Data Analysis

Radar On Market Access: MedImpact’s New Program Aims to Accelerate Pharmacogenomics

MMIT Reality Check on Endometriosis (June 2020)

Perspectives on ACA Exchanges Amid COVID-19

Radar On Market Access: Uncertainties Over Effectiveness and High Costs Surround DMD Therapies

Radar On Market Access: 2021 MA, Part D Bids Face Challenges Amid COVID-19

MMIT Reality Check on Chronic Idiopathic Constipation (June 2020)

Trends That Matter: The Future of Value-Based Agreements

Radar On Market Access: 1.7K Plans Apply for Trump Admin's Fixed-Insulin-Copay Program for Seniors

Radar On Market Access: Payers and PBMs May Play Key Role in COVID-19 Vaccine Rollout

MMIT Reality Check on Narcolepsy (May 2020)

Perspectives on Surge of Mental Health Meds Use Amid COVID-19

Radar On Market Access: Will COVID-19 Advance Automatic Health Insurance Enrollment?

Radar On Market Access: COVID-19 Pandemic May Change Rx Delivery Permanently

MMIT Reality Check on Low Testosterone (May 2020)

Trends That Matter for Medical-Benefit Drug Spending

Radar On Market Access: COVID-19 Pandemic Drives Home Infusion Utilization

Radar On Market Access: PBMs See Solid 1Q Results Despite Challenges Ahead

MMIT Reality Check on Pain Narcotic Opioid (May 2020)

Perspectives on Coronavirus Antibody Testing

Radar On Market Access: COVID-19 May Drive More Insurers Into ACA Exchanges

Radar On Market Access: CVS Sees COVID Testing Sites as Part of Bigger HealthHUB Strategy

MMIT Reality Check on Anemia — Chronic Kidney Disease (May 2020)

Trends That Matter for Biosimilar Medications Cost Savings

Radar On Market Access: Anthem, Cigna Brace for Recession-Induced Enrollment Shift

Radar On Market Access: Humana, Centene Maintain 2020 Earnings Outlook Amid COVID-19 Pandemic

MMIT Reality Check on Ophthalmic Anti-Inflammatory (Apr 2020)

Perspectives on ACA and Medicaid Enrollment Growth Amid COVID-19

Radar On Market Access: Oncology Drugs Drive Price Growth in Medical-Benefit Spend

Radar On Market Access: PBMs Say Use of Mental Health Meds Surges Amid COVID-19

MMIT Reality Check on Juvenile Idiopathic Arthritis (Apr 2020)

Trends That Matter for Bipolar Disorder Medications

Radar On Market Access: Medicaid MCOs Are Likely to See COVID-Related Enrollment Growth

Radar On Market Access: Insurers Are Now Required to Cover Coronavirus Antibody Testing

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2020)

Perspectives on COVID-19 Outbreak's Impact on Drug Supply

Radar On Market Access: Slow Biosimilar Adoption and Opaque Markets Impede Potential Savings

Radar On Market Access: PBMs Use Dispensing Limits to Halt Hoarding of Trump-Touted Malaria Drugs

MMIT Reality Check on Opioid Dependence (Apr 2020)

Trends That Matter for Cost Impact of Coronavirus Treatment

Radar On Market Access: Amid COVID-19 Outbreak, CMS Relaxes Rules on MA Data Collection

MMIT Reality Check on COPD (Apr 2020)

Perspectives on New Generic HIV Drug

Radar On Market Access: Congress Could Pass Medicare Part D Reform Even Amid COVID-19 Outbreak

MMIT Reality Check on Glaucoma (Mar 2020)

Trends That Matter for Asthma Medications

Radar On Market Access: ACA Plans and Medicaid May See Enrollment Growth Amid COVID-19 Pandemic

Radar On Market Access: Questions Remain About Cost Impact of Coronavirus Treatment

MMIT Reality Check on Major Depressive Disorder (Mar 2020)

Perspectives on Legality of Closed Medicaid Formularies

Radar On Market Access: COVID-19 Outbreak Could Impact Drug Supply Long-Term

Radar On Market Access: Insurers, Pharma Spar Over Copay Accumulator Provision

MMIT Reality Check on Hereditary Angioedema (Mar 2020)

Trends That Matter for Diabetes Drug Costs

Radar On Market Access: Insurers Deploy Array of Strategies to Manage Asthma

Radar On Market Access: Florida Saw Strong MA, Individual Results and More Consolidations

MMIT Reality Check on HIV (Mar 2020)

Perspectives on ACA Exchange Draft Regulation

Radar On Market Access: New Generic HIV Drug May Impact PrEP Coverage, Not HIV Coverage

Radar On Market Access: Tenn. Blues’ White Bagging Policy Sees Pushback from Providers

MMIT Reality Check on Rheumatoid Arthritis (Feb 2020)

Trends That Matter for Nebraska Medicaid Expansion

Radar on Market Access: Future of Medicaid Work Requirements Dims After Arkansas Demo Is Struck Down Again

Radar On Market Access: CVS Touts Aetna’s Contribution; Molina Exchange Business Stumbles

MMIT Reality Check on Type 2 Diabetes (GLP-1 and Combo) (Feb 2020)

Perspectives on Part D Reform in 2020

Radar On Market Access: Payers Try New Strategies to Control Diabetes Drug Costs

Radar On Market Access: Some Experts Question Legality of Closed Medicaid Formularies

MMIT Reality Check on Neutropenia (Feb 2020)

Trends That Matter for Kansas Medicaid Expansion

Radar On Market Access: ACA Exchange Draft Regulation Drops

Radar On Market Access: New Oncology Biosimilar Launches Could Prompt Preferencing

MMIT Reality Check on Multiple Sclerosis (Feb 2020)

Perspectives on Consolidated PBMs in 2020

Radar On Market Access: Sanofi Backs Away From U.S. PCSK9 Market, While Novartis Bets Big With Inclisiran

Radar on Market Access: Nebraska Proposes A Two-Tiered Medicaid Expansion

MMIT Reality Check on Immune Globulin (PID) (Jan 2020)

Radar on Market Access: Disappointing MCOs, Supreme Court Won't Expedite Obamacare Decision